相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update
Dennis Falzon et al.
EUROPEAN RESPIRATORY JOURNAL (2017)
Efficacy and safety of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional DMARDs in patients with RA at week 97 (SUMMACTA)
Gerd R. Burmester et al.
ANNALS OF THE RHEUMATIC DISEASES (2016)
Latent tuberculosis infection detection and active tuberculosis prevention in patients receiving anti-TNF therapy: an Italian nationwide survey
Fabrizio Cantini et al.
INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES (2016)
American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis
Michael M. Ward et al.
ARTHRITIS & RHEUMATOLOGY (2016)
Equal sensitivity of the new generation QuantiFERON-TB Gold plus in direct comparison with the previous test version QuantiFERON-TB Gold IT
H. Hoffmann et al.
CLINICAL MICROBIOLOGY AND INFECTION (2016)
Use of several immunological markers to model the probability of active tuberculosis
Elisa Petruccioli et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2016)
First evaluation of QuantiFERON-TB Gold Plus performance in contact screening
Lucia Barcellini et al.
EUROPEAN RESPIRATORY JOURNAL (2016)
First independent evaluation of QuantiFERON-TB Plus performance
Lucia Barcellini et al.
EUROPEAN RESPIRATORY JOURNAL (2016)
Tuberculosis care among refugees arriving in Europe: a ERS/WHO Europe Region survey of current practices
Masoud Dara et al.
EUROPEAN RESPIRATORY JOURNAL (2016)
Correlates of tuberculosis risk: predictive biomarkers for progression to active tuberculosis
Elisa Petruccioli et al.
EUROPEAN RESPIRATORY JOURNAL (2016)
Safety of secukinumab in the treatment of psoriasis
Andrew Blauvelt
EXPERT OPINION ON DRUG SAFETY (2016)
Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis
Silvia Minozzi et al.
EXPERT OPINION ON DRUG SAFETY (2016)
First characterization of the CD4 and CD8 T-cell responses to QuantiFERON-TB Plus
Elisa Petruccioli et al.
JOURNAL OF INFECTION (2016)
Early rheumatoid arthritis treated with tocilizumab, methotrexate, or their combination (U-Act-Early): a multicentre, randomised, double-blind, double-dummy, strategy trial
Johannes W. J. Bijlsma et al.
LANCET (2016)
A blood RNA signature for tuberculosis disease risk: a prospective cohort study
Daniel E. Zak et al.
LANCET (2016)
Lack of Response to HBHA in HIV-Infected Patients with Latent Tuberculosis Infection
G. Delogu et al.
SCANDINAVIAN JOURNAL OF IMMUNOLOGY (2016)
Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis
Fabrizio Cantini et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2016)
Addressing diabetes mellitus as part of the strategy for ending TB
Anthony D. Harries et al.
TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE (2016)
TB vaccine development and the End TB Strategy: importance and current status
Helen A. Fletcher et al.
TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE (2016)
T-cell activation is an immune correlate of risk in BCG vaccinated infants
Helen A. Fletcher et al.
NATURE COMMUNICATIONS (2016)
The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling
Rein M. G. J. Houben et al.
PLOS MEDICINE (2016)
Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis
Laura C. Coates et al.
ARTHRITIS & RHEUMATOLOGY (2016)
The Intelligent Control System and Experiments for an Unmanned Wave Glider (Publication with Expression of Concern. See vol. 17, 2022)
Yulei Liao et al.
PLOS ONE (2016)
Evaluation of QuantiFERON-TB Gold Plus for Detection of Mycobacterium tuberculosis infection in Japan
Lina Yi et al.
SCIENTIFIC REPORTS (2016)
Tuberculosis 2015: burden, challenges and strategy for control and elimination
Mario Raviglione et al.
INFECTIOUS DISEASE REPORTS (2016)
Tuberculosis biomarkers: from diagnosis to protection
Delia Goletti et al.
INFECTIOUS DISEASE REPORTS (2016)
Risk Assessment of Tuberculosis in Contacts by IFN-γ Release Assays A Tuberculosis Network European Trials Group Study
Jean-Pierre Zellweger et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2015)
Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice
Fabrizio Cantini et al.
AUTOIMMUNITY REVIEWS (2015)
Comparison of tocilizumab as monotherapy or with add-on disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and inadequate responses to previous treatments: an open-label study close to clinical practice
Vivian P. Bykerk et al.
CLINICAL RHEUMATOLOGY (2015)
Towards tuberculosis elimination: an action framework for low-incidence countries
Knut Loennroth et al.
EUROPEAN RESPIRATORY JOURNAL (2015)
Acquired immunodeficiencies and tuberculosis: focus on HIV/AIDS and diabetes mellitus
Katharina Ronacher et al.
IMMUNOLOGICAL REVIEWS (2015)
Co-evolution of Mycobacterium tuberculosis and Homo sapiens
Daniela Brites et al.
IMMUNOLOGICAL REVIEWS (2015)
Cytokine and lipid mediator networks in tuberculosis
Katrin D. Mayer-Barber et al.
IMMUNOLOGICAL REVIEWS (2015)
Assessment of CD27 expression as a tool for active and latent tuberculosis diagnosis
Elisa Petruccioli et al.
JOURNAL OF INFECTION (2015)
Longterm Efficacy and Safety of Abatacept in Patients with Rheumatoid Arthritis Treated in Routine Clinical Practice: Effect of Concomitant Methotrexate after 24 Weeks
Nobunori Takahashi et al.
JOURNAL OF RHEUMATOLOGY (2015)
Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial
Iain B. McInnes et al.
LANCET (2015)
Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis
Dominique Baeten et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis
Philip J. Mease et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Mycobacterium tuberculosis-specific CD4 T cells are the principal source of IFN-γ in QuantiFERON assays in healthy persons
Adam Penn-Nicholson et al.
TUBERCULOSIS (2015)
Maintenance of Clinical Efficacy and Radiographic Benefit Through Two Years of Ustekinumab Therapy in Patients With Active Psoriatic Arthritis: Results From a Randomized, Placebo-Controlled Phase III Trial
Arthur Kavanaugh et al.
ARTHRITIS CARE & RESEARCH (2015)
Head-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical practice: results from the registry of Japanese RA patients on biologics for long-term safety (REAL) registry
Ryoko Sakai et al.
ARTHRITIS RESEARCH & THERAPY (2015)
Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR)
Robert E. Kalb et al.
JAMA DERMATOLOGY (2015)
Biomarkers Can Identify Pulmonary Tuberculosis in HIV-infected Drug Users Months Prior to Clinical Diagnosis
Rosa Sloot et al.
EBIOMEDICINE (2015)
Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period
Paul Emery et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
Combined Use of Mycobacterium tuberculosis-Specific CD4 and CD8 T-Cell Responses Is a Powerful Diagnostic Tool of Active Tuberculosis
Virginie Rozot et al.
CLINICAL INFECTIOUS DISEASES (2015)
Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial
Iain B. McInnes et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial
Michael Schiff et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study)
Gerd R. Burmester et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update
Josef S. Smolen et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study
Maxime Dougados et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial
Christopher Ritchlin et al.
ANNALS OF THE RHEUMATIC DISEASES (2014)
Polyfunctional T-cells and effector memory phenotype are associated with active TB in HIV-infected patients
Teresa Chiacchio et al.
JOURNAL OF INFECTION (2014)
Longterm Safety, Efficacy, and Inhibition of Structural Damage Progression Over 5 Years of Treatment with Abatacept in Patients with Rheumatoid Arthritis in the Abatacept in Inadequate Responders to Methotrexate Trial
Joel M. Kremer et al.
JOURNAL OF RHEUMATOLOGY (2014)
Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy
Norihiro Nishimoto et al.
Modern Rheumatology (2014)
Remission in patients with active rheumatoid arthritis by tocilizumab treatment in routine clinical practice: results from 3 years of prospectively registered data
Yasuharu Nakashima et al.
MODERN RHEUMATOLOGY (2014)
Assessment of the novel T-cell activation marker-tuberculosis assay for diagnosis of active tuberculosis in children: a prospective proof-of-concept study
Damien Portevin et al.
LANCET INFECTIOUS DISEASES (2014)
In search of a new paradigm for protective immunity to TB
Cludio Nunes-Alves et al.
NATURE REVIEWS MICROBIOLOGY (2014)
The ongoing challenge of latent tuberculosis
H. Esmail et al.
PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES (2014)
Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies
Alejandro Souto et al.
RHEUMATOLOGY (2014)
Subcutaneous Tocilizumab Versus Placebo in Combination With Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid Arthritis
Alan Kivitz et al.
ARTHRITIS CARE & RESEARCH (2014)
Phase III Study of the Efficacy and Safety of Subcutaneous Versus Intravenous Tocilizumab Monotherapy in Patients With Rheumatoid Arthritis
Atsushi Ogata et al.
ARTHRITIS CARE & RESEARCH (2014)
Rituximab in patients with rheumatoid arthritis in routine practice (GERINIS): six-year results from a prospective, multicentre, non-interventional study in 2,484 patients
Joerg Wendler et al.
ARTHRITIS RESEARCH & THERAPY (2014)
Unexpected Role for IL-17 in Protective Immunity against Hypervirulent Mycobacterium tuberculosis HN878 Infection
Radha Gopal et al.
PLOS PATHOGENS (2014)
Functional signatures of human CD4 and CD8T cell responses to Mycobacterium tuberculosis
Teresa Prezzemolo et al.
FRONTIERS IN IMMUNOLOGY (2014)
Adalimumab, Etanercept, Infliximab, and the Risk of Tuberculosis: Data from Clinical Trials, National Registries, and Postmarketing Surveillance
Fabrizio Cantini et al.
JOURNAL OF RHEUMATOLOGY (2014)
Tuberculosis Risk in Patients Treated with Non-Anti-Tumor Necrosis Factor-α (TNF-α) Targeted Biologics and Recently Licensed TNF-α Inhibitors: Data from Clinical Trials and National Registries
Fabrizio Cantini et al.
JOURNAL OF RHEUMATOLOGY (2014)
Performance of the Tuberculin Skin Test and Interferon-γ Release Assays: An Update on the Accuracy, Cutoff Stratification, and New Potential Immune-based Approaches
Delia Goletti et al.
JOURNAL OF RHEUMATOLOGY (2014)
The Spectrum of Tuberculosis Infection: New Perspectives in the Era of Biologics
Giovanni Delogu et al.
JOURNAL OF RHEUMATOLOGY (2014)
Tocilizumab in patients with active rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs or tumor necrosis factor inhibitors: subanalysis of Spanish results of an open-label study close to clinical practice
Jose M. Alvaro-Gracia et al.
REUMATOLOGIA CLINICA (2014)
Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients
Ronald F. van Vollenhoven et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY)
Maxime Dougados et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Autophagy in Mycobacterium tuberculosis infection: A passepartout to flush the intruder out?
Delia Goletti et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2013)
Antigen-specific CD4- and CD8-positive signatures in different phases of Mycobacterium tuberculosis infection
Maria Nikolova et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2013)
Mycobacterium tuberculosis-specific CD8+ T cells are functionally and phenotypically different between latent infection and active disease
Virginie Rozot et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2013)
Knee tuberculosis under rituximab therapy for rheumatoid arthritis
Sebastien Ottaviani et al.
JOINT BONE SPINE (2013)
IL-1β Promotes Antimicrobial Immunity in Macrophages by Regulating TNFR Signaling and Caspase-3 Activation
Pushpa Jayaraman et al.
JOURNAL OF IMMUNOLOGY (2013)
Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial
Iain B. McInnes et al.
LANCET (2013)
Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial
Cem Gabay et al.
LANCET (2013)
Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial
Dominique Baeten et al.
LANCET (2013)
IGRAs - The gateway to T cell based TB diagnosis
Hilary S. Whitworth et al.
METHODS (2013)
Randomised Clinical Trial Investigating the Specificity of a Novel Skin Test (C-Tb) for Diagnosis of M. tuberculosis Infection
Henrik Aggerbeck et al.
PLOS ONE (2013)
Demographic Variables for Wild Asian Elephants Using Longitudinal Observations
Shermin de Silva et al.
PLOS ONE (2013)
The effects of rituximab therapy on released interferon-γ levels in the QuantiFERON assay among RA patients with different status of Mycobacterium tuberculosis infection
Yi-Ming Chen et al.
RHEUMATOLOGY (2013)
Efficacy of tocilizumab in patients with moderate to severe active rheumatoid arthritis and a previous inadequate response to disease-modifying antirheumatic drugs: the ROSE study
Yusuf Yazici et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Abatacept in subjects who switch from intravenous to subcutaneous therapy: results from the phase IIIb ATTUNE study
Edward Clark Keystone et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Tocilizumab in patients with active rheumatoid arthritis and inadequate responses to DMARDs and/or TNF inhibitors: a large, open-label study close to clinical practice
Vivian P. Bykerk et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
Comparative effectiveness of switching to alternative tumour necrosis factor (TNF) antagonists versus switching to rituximab in patients with rheumatoid arthritis who failed previous TNF antagonists: the MIRAR Study
Juan J. Gomez-Reino et al.
ANNALS OF THE RHEUMATIC DISEASES (2012)
The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection
T. -F. Tsai et al.
BRITISH JOURNAL OF DERMATOLOGY (2012)
The risk of tuberculosis in transplant candidates and recipients: a TBNET consensus statement
Dragos Bumbacea et al.
EUROPEAN RESPIRATORY JOURNAL (2012)
Safety of rituximab in rheumatoid arthritis: A long-term prospective single-center study of gammaglobulin concentrations and infections
Anne Isvy et al.
JOINT BONE SPINE (2012)
Specific T Cells Restore the Autophagic Flux Inhibited by Mycobacterium tuberculosis in Human Primary Macrophages
Elisa Petruccioli et al.
JOURNAL OF INFECTIOUS DISEASES (2012)
Predictive value of interferon-gamma release assays for incident active tuberculosis: a systematic review and meta-analysis
Molebogeng X. Rangaka et al.
LANCET INFECTIOUS DISEASES (2012)
Improvements in health-related quality of life after treatment with tocilizumab in patients with rheumatoid arthritis refractory to tumour necrosis factor inhibitors: results from the 24-week randomized controlled RADIATE study
Vibeke Strand et al.
RHEUMATOLOGY (2012)
2012 Update of the 2008 American College of Rheumatology Recommendations for the Use of Disease-Modifying Antirheumatic Drugs and Biologic Agents in the Treatment of Rheumatoid Arthritis
Jasvinder A. Singh et al.
ARTHRITIS CARE & RESEARCH (2012)
Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA)
Gerd R. Burmester et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial
P. P. Tak et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis
Maya H. Buch et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial
Joel M. Kremer et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients
Takao Koike et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis
J. Braun et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
B Cell Activation Biomarkers as Predictive Factors for the Response to Rituximab in Rheumatoid Arthritis
Jeremie Sellam et al.
ARTHRITIS AND RHEUMATISM (2011)
Tocilizumab Inhibits Structural Joint Damage in Rheumatoid Arthritis Patients With Inadequate Responses to Methotrexate Results From the Double-Blind Treatment Phase of a Randomized Placebo-Controlled Trial of Tocilizumab Safety and Prevention of Structural Joint Damage at One Year
Joel M. Kremer et al.
ARTHRITIS AND RHEUMATISM (2011)
Subcutaneous Abatacept Versus Intravenous Abatacept A Phase IIIb Noninferiority Study in Patients With an Inadequate Response to Methotrexate
M. C. Genovese et al.
ARTHRITIS AND RHEUMATISM (2011)
Evaluation of the Safety of Rituximab in Combination With a Tumor Necrosis Factor Inhibitor and Methotrexate in Patients With Active Rheumatoid Arthritis Results From a Randomized Controlled Trial
Maria W. Greenwald et al.
ARTHRITIS AND RHEUMATISM (2011)
Regulation of neutrophils by interferon-γ limits lung inflammation during tuberculosis infection
Bisweswar Nandi et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2011)
Functional Capacity of Mycobacterium tuberculosis-Specific T Cell Responses in Humans Is Associated with Mycobacterial Load
Cheryl L. Day et al.
JOURNAL OF IMMUNOLOGY (2011)
Safety and Effectiveness of Rituximab in Patients with Rheumatoid Arthritis Following an Inadequate Response to 1 Prior Tumor Necrosis Factor Inhibitor: The RESET Trial
Boulos Haraoui et al.
JOURNAL OF RHEUMATOLOGY (2011)
Tocilizumab Monotherapy Reduces Arterial Stiffness as Effectively as Etanercept or Adalimumab Monotherapy in Rheumatoid Arthritis: An Open-label Randomized Controlled Trial
Kensuke Kume et al.
JOURNAL OF RHEUMATOLOGY (2011)
Efficacy and tolerability of tocilizumab in rheumatoid arthritis patients seen in daily clinical practice in Japan: results from a retrospective study (REACTION study)
Hisashi Yamanaka et al.
MODERN RHEUMATOLOGY (2011)
Rv3615c is a highly immunodominant RD1 (Region of Difference 1)-dependent secreted antigen specific for Mycobacterium tuberculosis infection
Kerry A. Millington et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries
Xavier Mariette et al.
RHEUMATOLOGY (2011)
Clinical, radiographic and functional effectiveness of tocilizumab for rheumatoid arthritis patients-REACTION 52-week study
Tsutomu Takeuchi et al.
RHEUMATOLOGY (2011)
Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID)
Hans-Peter Tony et al.
ARTHRITIS RESEARCH & THERAPY (2011)
Integrated safety in tocilizumab clinical trials
Michael H. Schiff et al.
ARTHRITIS RESEARCH & THERAPY (2011)
Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study
G. Jones et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial)
P. Emery et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE))
P. Emery et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Risk Factors for Severe Infections in Patients With Rheumatoid Arthritis Treated With Rituximab in the AutoImmunity and Rituximab Registry
J. -E. Gottenberg et al.
ARTHRITIS AND RHEUMATISM (2010)
Role of Th17 Cells in Human Autoimmune Arthritis
Jan Leipe et al.
ARTHRITIS AND RHEUMATISM (2010)
How tumour necrosis factor blockers interfere with tuberculosis immunity
J. Harris et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2010)
The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement
I. Solovic et al.
EUROPEAN RESPIRATORY JOURNAL (2010)
Mycobacterium bovis BCG-Specific Th17 Cells Confer Partial Protection against Mycobacterium tuberculosis Infection in the Absence of Gamma Interferon
Teresa M. Wozniak et al.
INFECTION AND IMMUNITY (2010)
Pathological role of interleukin 17 in mice subjected to repeated BCG vaccination after infection with Mycobacterium tuberculosis
Andrea Cruz et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2010)
Efficacy and Safety of Retreatment in Patients with Rheumatoid Arthritis with Previous Inadequate Response to Tumor Necrosis Factor Inhibitors: Results from the SUNRISE Trial
Philip J. Mease et al.
JOURNAL OF RHEUMATOLOGY (2010)
Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR)
Andrea Rubbert-Roth et al.
RHEUMATOLOGY (2010)
Clinical efficacy of tocilizumab in patients with active rheumatoid arthritis in real clinical practice
Yasuhiko Hirabayashi et al.
RHEUMATOLOGY INTERNATIONAL (2010)
The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial
M. Schiff et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors
R. Westhovens et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement
U. Mack et al.
EUROPEAN RESPIRATORY JOURNAL (2009)
Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy
Norihiro Nishimoto et al.
MODERN RHEUMATOLOGY (2009)
Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial
Alice Gottlieb et al.
LANCET (2009)
The spectrum of latent tuberculosis: rethinking the biology and intervention strategies
Clifton E. Barry et al.
NATURE REVIEWS MICROBIOLOGY (2009)
IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial
P. Emery et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate
M. Schiff et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
Interleukin-6 Receptor Inhibition With Tocilizumab Reduces Disease Activity in Rheumatoid Arthritis With Inadequate Response to Disease-Modifying Antirheumatic Drugs The Tocilizumab in Combination With Traditional Disease-Modifying Antirheumatic Drug Therapy Study
Mark C. Genovese et al.
ARTHRITIS AND RHEUMATISM (2008)
Disease Activity-Guided Rituximab Therapy in Rheumatoid Arthritis The Effects of Re-Treatment in Initial Nonresponders Versus Initial Responders
Rogier M. Thurlings et al.
ARTHRITIS AND RHEUMATISM (2008)
Mycobacterial and other serious infections in patients receiving anti-tumor necrosis factor and other newly approved biologic therapies: Case finding through the emerging infections network
Kevin L. Winthrop et al.
CLINICAL INFECTIOUS DISEASES (2008)
Distinct, specific IL-17- and IL-22-producing CD4+ T cell subsets contribute to the human anti-mycobacterial immune response
Thomas J. Scriba et al.
JOURNAL OF IMMUNOLOGY (2008)
Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial
Josef S. Smolen et al.
LANCET (2008)
Rituximab use in everyday clinical practice as a first-line biologic therapy for the treatment of DMARD-resistant rheumatoid arthritis
D. McGonagle et al.
RHEUMATOLOGY (2008)
Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): Evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab
Norihiro Nishimoto et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
Mycobacterium tuberculosis infects dendritic cells with high frequency and impairs their function in vivo
Andrea J. Wolf et al.
JOURNAL OF IMMUNOLOGY (2007)
Rituximab therapy in patients with resistant rheumatoid arthritis: real-life experience
R. N. Jois et al.
RHEUMATOLOGY (2007)
IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge
Shabaana A. Khader et al.
NATURE IMMUNOLOGY (2007)
Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial
Michael Weinblatt et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
Evolution and expansion of the Mycobacterium tuberculosis PE and PPE multigene families and their association with the duplication of the ESAT-6 (esx) gene cluster regions
Nicolaas C. Gey van Pittius et al.
BMC EVOLUTIONARY BIOLOGY (2006)
Improved health-related quality of life for rheumatoid arthritis patients treated with abatacept who have inadequate response to anti-TNF therapy in a double-blind, placebo-controlled, multicentre randomized clinical trial
R. Westhovens et al.
RHEUMATOLOGY (2006)
Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy - Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks
Stanley B. Cohen et al.
ARTHRITIS AND RHEUMATISM (2006)
Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs - A one-year randomized, placebo-controlled study
M. Weinblatt et al.
ARTHRITIS AND RHEUMATISM (2006)
Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate
R. N. Maini et al.
ARTHRITIS AND RHEUMATISM (2006)
Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis - A randomized trial
Joel M. Kremer et al.
ANNALS OF INTERNAL MEDICINE (2006)
The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment - Results of a phase IIb randomized, double-blind, placebo-controlled, dose-ranging trial
P Emery et al.
ARTHRITIS AND RHEUMATISM (2006)
Variable host-pathogen compatibility in Mycobacterium tuberculosis
S Gagneux et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Hypervirulent M-tuberculosis W/Beijing strains upregulate type IIFNs and increase expression of negative regulators of the Jak-Stat pathway
C Manca et al.
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH (2005)
Abatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition
MC Genovese et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept - Twelve-month results of a phase IIb, double-blind, randomized, placebo-controlled trial
JM Kremer et al.
ARTHRITIS AND RHEUMATISM (2005)
Specific detection of tuberculosis infection an interferon-γ-based assay using new antigens
T Mori et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2004)
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
JCW Edwards et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody - A multicenter, double-blind, placebo-controlled trial
N Nishimoto et al.
ARTHRITIS AND RHEUMATISM (2004)
Rab7 is required for the normal progression of the autophagic pathway in mammalian cells
MG Gutierrez et al.
JOURNAL OF CELL SCIENCE (2004)
Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig
JM Kremer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Dissemination of Mycobacterium tuberculosis is influenced by host factors and precedes the initiation of T-cell immunity
AA Chackerian et al.
INFECTION AND IMMUNITY (2002)
Analysis of nitric oxide synthase and nitrotyrosine expression in human pulmonary tuberculosis
HS Choi et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2002)
Costimulatory blockade in patients with rheumatoid arthritis a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion
LW Moreland et al.
ARTHRITIS AND RHEUMATISM (2002)
Virulence of a Mycobacterium tuberculosis clinical isolate in mice is determined by failure to induce Th1 type immunity and is associated with induction of IFN-α/β
C Manca et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: Possible role for limiting pathology
VP Mohan et al.
INFECTION AND IMMUNITY (2001)
Specific immune-based diagnosis of tuberculosis
P Andersen et al.
LANCET (2000)
分享论文
